Protocol

Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)

Fragmentation pattern comparison by Hou et al. 2024.

Overview

Fragmentation pattern comparison by Hou et al. 2024.

Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.

10 recorded evaluations, 220 metric rows. A comparison chart has not yet been validated for these results. The table retains the individual findings and their sources.

View coverage and remaining gaps across all benchmarks

Results

Results are available, but no reviewed comparison panel is linked in this release.

All evaluations

10 evaluations · 220 results. Different protocols are not a single leaderboard.

Filter evaluations

Tested model or methodProtocolDatasetEvaluation setupMetricEvidence origin

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configuration	Protocol and dataset	Finding	Evidence and details
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.985 auroc unitless · higher Uncertainty: 95% CI 0.9805 to 0.9898 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C22; group 'BRCA'; row 'EDM'; column 'AUC'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.932 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.9073 to 0.9574 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E22; group 'BRCA'; row 'EDM'; column 'Sensitivity @85% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.838 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.7936 to 0.8824 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D22; group 'BRCA'; row 'EDM'; column 'Sensitivity @95% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.99 auroc unitless · higher Uncertainty: 95% CI 0.9850 to 0.9951 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C32; group 'CHOL'; row 'EDM'; column 'AUC'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.955 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.9289 to 0.9811 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E32; group 'CHOL'; row 'EDM'; column 'Sensitivity @85% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.917 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.8838 to 0.9495 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D32; group 'CHOL'; row 'EDM'; column 'Sensitivity @95% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	1 auroc unitless · higher Uncertainty: 95% CI 0.9991 to 1.0000 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C42; group 'CRC'; row 'EDM'; column 'AUC'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	1 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 1.0000 to 1.0000 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E42; group 'CRC'; row 'EDM'; column 'Sensitivity @85% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.993 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.9803 to 1.0000 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D42; group 'CRC'; row 'EDM'; column 'Sensitivity @95% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.998 auroc unitless · higher Uncertainty: 95% CI 0.9957 to 0.9997 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C62; group 'NSCLC'; row 'EDM'; column 'AUC'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	1 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 1.0000 to 1.0000 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E62; group 'NSCLC'; row 'EDM'; column 'Sensitivity @85% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.95 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.9073 to 0.9927 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D62; group 'NSCLC'; row 'EDM'; column 'Sensitivity @95% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.989 auroc unitless · higher Uncertainty: 95% CI 0.9849 to 0.9930 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C72; group 'OV'; row 'EDM'; column 'AUC'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.958 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.9293 to 0.9873 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E72; group 'OV'; row 'EDM'; column 'Sensitivity @85% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.82 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.7618 to 0.8782 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D72; group 'OV'; row 'EDM'; column 'Sensitivity @95% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.954 auroc unitless · higher Uncertainty: 95% CI 0.9421 to 0.9667 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C82; group 'PAAD'; row 'EDM'; column 'AUC'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.873 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.8396 to 0.9054 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E82; group 'PAAD'; row 'EDM'; column 'Sensitivity @85% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.817 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.7751 to 0.8582 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D82; group 'PAAD'; row 'EDM'; column 'Sensitivity @95% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.974 auroc unitless · higher Uncertainty: 95% CI 0.9696 to 0.9776 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C12; group 'PANCAN'; row 'EDM'; column 'AUC'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.963 auroc unitless · higher Uncertainty: 95% CI 0.9435 to 0.9819 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C52; group 'STAD'; row 'EDM'; column 'AUC'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.92 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.8875 to 0.9525 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E52; group 'STAD'; row 'EDM'; column 'Sensitivity @85% specificity'
Configuration: Fragment 5' end motif (4-mer), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.897 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.8586 to 0.9347 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source EDM (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D52; group 'STAD'; row 'EDM'; column 'Sensitivity @95% specificity'
Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.975 auroc unitless · higher Uncertainty: 95% CI 0.9651 to 0.9843 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source coverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C17; group 'BRCA'; row 'coverage'; column 'AUC'
Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.947 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.9280 to 0.9660 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source coverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E17; group 'BRCA'; row 'coverage'; column 'Sensitivity @85% specificity'
Configuration: Fragment coverage (fragment midpoint counts), open chromatin regions, SVM (Hou et al. 2024)	Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2) Dataset: DELFI 2019 internally cross-validated cancer detection cohort	0.885 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.8566 to 0.9134 Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source coverage (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D17; group 'BRCA'; row 'coverage'; column 'Sensitivity @95% specificity'

Source checking is not independent reproduction. Release 2026-10-09-ba02f2f4a36e.

Methods and evaluation design

Procedure, tasks and evaluated configurations

Recorded evaluations

Each evaluation records what was tested and under which conditions.

Baseline coverage

Reference methods help show what a model adds beyond simple controls. We track a null control and a conventional method for each protocol.

0 of 2 active baseline roles have published Rewire measurements in this release. Measurements on a selected protocol do not establish coverage of an entire suite.

No execution recipe linked to this protocol. Recipe availability does not establish a completed evaluation.

Author-reported evaluations: 1
External evaluations: 9

Literature evidence is not a Rewire measurement. Executed but unpublished runs and private review status are not included.

Null control

Proposed control: requires review

Select a task-valid null control after reviewing inputs and metric

Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.

This is a suggested selection rule, not a validated method or a measured score.

Conventional reference

Proposed control: requires review

Select an upstream conventional reference after reviewing the full protocol

Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.

This is a suggested selection rule, not a validated method or a measured score.

Protocol coverage CSV (gzip) · Model evaluation matrix (gzip) · Source table (gzip) · Release and checksums (gzip)

Coverage is derived from release 2026-10-09-ba02f2f4a36e. Source citations describe the original records; they do not validate an unreviewed baseline proposal. No results have been generated by this audit.

Run instructions

No runnable recipe has been reviewed for this protocol. Dataset access, model requirements, licences and compute requirements must be checked against its sources before execution.

Strengths, limitations and unresolved questions

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

0 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-10-09-ba02f2f4a36e
Property and statement	Original source and location	Review and provenance

No evidence rows match these filters. Choose another scope or clear the search.

All evidence (JSONL) (gzip)How to read the evidence

Sources and history

Release 2026-10-09-ba02f2f4a36e · Record review: source checked

2 source records and release history

Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns · Original source · Advanced Science 11(30):e2308243, published 2024-06-17; PMC11321639 full-text XML
Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Original source · ADVS-11-2308243-s001.xlsx, PMC open-access copy PMC11321639.1

Download this release (gzip)

Technical metadata and extraction receipts

Stable ID: ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity

areas: dna-genomes
contexts: clinical_research
protocol: Pan-cancer and per-cancer-type SVMs against the 215 healthy individuals; 10 repeats of 10-fold cross-validation. Report ROC-AUC and sensitivity at 95% and at 85% specificity.
version: Hou et al. 2024 Supporting Information; Methods P41, P44, P45
metric: auroc
metric direction: higher
limitations: Table S2 pan-cancer sensitivities are disputed: the column labelled 85% specificity holds the Table S9 values at 95%, and Tables S9 and S10 support Table S9. The per-cancer sensitivities have no second table to check against.; Ten fragmentation patterns restricted to open chromatin regions, one SVM each; no tumour-fraction stratification.; Per-cancer-type groups are small (12 to 54 patients).; IFS was defined by Hou et al.'s corresponding author (Zhou et al. 2022, ref 10), so its evaluations are author-reported; the other nine patterns are independent re-implementations.
source locator: Supporting Information Table S2 rows 3-82; Experimental Section P41, P44, P45

Related records

uses data: DELFI 2019 internally cross-validated cancer detection cohort
assessment: EDM (open chromatin), Cristiano cohort cross-validation
assessment: coverage (open chromatin), Cristiano cohort cross-validation
assessment: end (open chromatin), Cristiano cohort cross-validation
assessment: length (open chromatin), Cristiano cohort cross-validation
assessment: FSD (open chromatin), Cristiano cohort cross-validation
assessment: FSR (open chromatin), Cristiano cohort cross-validation
assessment: IFS (open chromatin), Cristiano cohort cross-validation
assessment: OCF (open chromatin), Cristiano cohort cross-validation
assessment: PFE (open chromatin), Cristiano cohort cross-validation
assessment: WPS (open chromatin), Cristiano cohort cross-validation
assessed by: Select a plasma ctDNA fragmentomics detection workflow

Suggest a correction